

Peer Review File

Article information: <https://dx.doi.org/10.21037/tlcr-23-290>

Reviewer A

Comment 1: I suggest clarification how PFS-2 was measured or defined.

Reply 1: The definition of PFS-2 has been added to the text (see Page 2, line 74).

Reviewer B

Comment 1: Line 109-110. The authors would also like to refer to reports on other clinical biomarkers for response to ICI monotherapy.

Reply 1: A brief mention of other clinical predictive biomarkers has been included (see Page 3, line 117).

Reviewer C

Comment 1: 5-year OS with chemotherapy alone (i.e., prior to use of immunotherapy.).

Reply 1: 5-year OS in the placebo arm is mentioned in the text (line 89). A further reference about previous survival data has been added (see Page 3, line 90).

Comment 2: Mention of other chemo-immunotherapy regimens (i.e., CheckMate 9LA) and difficulties in knowing which protocol is best (ie., potential use of IPI/NIVO/chemo for patients with brain metastases or tumors with PDL1 TPS<1%).

Reply 2: A paragraph introducing the CheckMate 9LA trial and the relevant results has been included (see Page 3, line 120).

Comment 3: Major limitation of the trial excluding patients with poor ECOG performance status.

Reply 3: We have added a comment about ECOG ≥ 2 and symptomatic brain metastases as exclusion criteria (see Page 2, line 69).